Gene:
AGTR1
angiotensin II receptor, type 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for AGTR1

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs12721226 NC_000003.11:g.148459309G>A, NC_000003.12:g.148741522G>A, NG_008468.1:g.48652G>A, NM_000685.4:c.487G>A, NM_004835.4:c.592G>A, NM_009585.3:c.487G>A, NM_031850.3:c.592G>A, NM_032049.3:c.574G>A, NP_000676.1:p.Ala163Thr, NP_004826.5:p.Ala198Thr, NP_033611.1:p.Ala163Thr, NP_114038.4:p.Ala198Thr, NP_114438.2:p.Ala192Thr, rs17231252, rs58583575
G > A
SNP
A163T
No VIP available No Clinical Annotations available VA
rs2640543 NC_000003.11:g.148432369A>G, NC_000003.12:g.148714582A>G, NG_008468.1:g.21712A>G, NM_000685.4:c.-48+6555A>G, NM_004835.4:c.1-15598A>G, NM_009585.3:c.-48+16455A>G, NM_031850.3:c.-1+6555A>G, rs17237176, rs59156576
A > G
SNP
No VIP available CA VA
rs275651 NC_000003.11:g.148414887T>A, NC_000003.12:g.148697100T>A, NG_008468.1:g.4230T>A, NM_000685.4:c.-1159T>A, NM_004835.4:c.-1028T>A, NM_009585.3:c.-1075T>A, NM_031850.3:c.-1112T>A, rs111181444, rs17230455, rs1800768, rs3755646, rs60031984, rs61174253, rs770424, rs770637
T > A
SNP
No VIP available CA VA
rs5182 NC_000003.11:g.148459395C>T, NC_000003.12:g.148741608C>T, NG_008468.1:g.48738C>T, NM_000685.4:c.573C>T, NM_004835.4:c.678C>T, NM_009585.3:c.573C>T, NM_031850.3:c.678C>T, NM_032049.3:c.660C>T, NP_000676.1:p.Leu191=, NP_004826.5:p.Leu226=, NP_033611.1:p.Leu191=, NP_114038.4:p.Leu226=, NP_114438.2:p.Leu220=, rs17231259, rs17845691, rs17858633, rs275648, rs3772606, rs56755191
C > T
SNP
L191L
No VIP available CA VA
rs5186 NC_000003.11:g.148459988A>C, NC_000003.12:g.148742201A>C, NG_008468.1:g.49331A>C, NM_000685.4:c.*86A>C, NM_004835.4:c.*86A>C, NM_009585.3:c.*86A>C, NM_031850.3:c.*86A>C, NM_032049.3:c.*86A>C, rs17231380, rs3192044, rs3732563, rs386597902, rs59796105
A > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  AGTR1B
Alternate Symbols:  AG2S; AGTR1A; AT1; AT1B; AT2R1; AT2R1A; AT2R1B; HAT1R
PharmGKB Accession Id: PA43

Details

Cytogenetic Location: chr3 : q24 - q24
GP mRNA Boundary: chr3 : 148415658 - 148460790
GP Gene Boundary: chr3 : 148405658 - 148463790
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. ACE Inhibitor Pathway, Pharmacodynamics
    Model, non-tissue-specific cell displaying genes which may be involved in the ACE inhibitor pathway
  1. Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics
    Genes involved in the pharmacodynamics of the drugs that act on the renin-angiotensin-aldosterone system.
  1. Losartan Pathway, Pharmacokinetics
    Representation of the candidate genes involved in the metabolism of losartan.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
CYP11B2

Curated Information ?

Curated Information ?

Publications related to AGTR1: 44

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy. Pharmacogenomics. 2016. Agarwal Aniruddha, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Individualized Angiotensin-Converting Enzyme (ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. Journal of the American Heart Association. 2016. Oemrawsingh Rohit M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension pharmacogenomics: in search of personalized treatment approaches. Nature reviews. Nephrology. 2015. Cooper-DeHoff Rhonda M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human pharmacogenomic variation of antihypertensive drugs: from population genetics to personalized medicine. Pharmacogenomics. 2014. Polimanti Renato, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation-optimized treatment benefit of angiotensin-converting enzyme inhibitors in patients with stable coronary artery disease: a 12-year follow-up study. Pharmacogenetics and genomics. 2013. Lee Jen-Kuang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the heptahelical receptor regulators G-protein-coupled receptor kinases and arrestins: the known and the unknown. Pharmacogenomics. 2012. Lymperopoulos Anastasios, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms, hypertension and thiazide diuretics. Pharmacogenomics. 2011. Citterio Lorena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan. Journal of hypertension. 2011. Jiang Shanqun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interactions of renin-angiotensin system gene polymorphisms and antihypertensive effect of benazepril in Chinese population. Pharmacogenomics. 2011. Chen Qing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Contribution of deletion in angiotensin-converting enzyme but not A1166C angiotensin II type-1 receptor gene polymorphisms to clinical outcomes in atherothrombotic disease. Archives of medical research. 2011. Le Hello Claire, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics. 2010. Brugts Jasper J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity. Pharmacogenetics and genomics. 2010. Arsenault Jason, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Demonstrating the pharmacogenetic effects of angiotensin-converting enzyme inhibitors on long-term prognosis of diastolic heart failure. The pharmacogenomics journal. 2010. Wu C-K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. American journal of hypertension. 2009. Bozkurt Ozlem, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2009. Brugts J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of a polymorphism of the apolipoprotein E gene with chronic kidney disease in Japanese individuals with metabolic syndrome. Genomics. 2009. Yoshida Tetsuro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of renin-angiotensin system polymorphisms on renal haemodynamic responsiveness to acute angiotensin-converting enzyme inhibition in type 2 diabetes mellitus. Journal of the renin-angiotensin-aldosterone system : JRAAS. 2009. Volkan-Salanci Bilge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: results from the GENRES study. American journal of hypertension. 2009. Suonsyrjä Timo, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes. Pharmacogenetics and genomics. 2008. Knouff Christopher W, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. The pharmacogenomics journal. 2008. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan. The Annals of pharmacotherapy. 2008. de Denus Simon, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Are we poised to target ACE2 for the next generation of antihypertensives?. Journal of molecular medicine (Berlin, Germany). 2008. Ferreira Anderson J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arteriosclerosis, thrombosis, and vascular biology. 2007. Mogi Masaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. American journal of human genetics. 2007. Sethupathy Praveen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert opinion on pharmacotherapy. 2007. Athyros Vasilios G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Quantitated transcript haplotypes (QTH) of AGTR1, reduced abundance of mRNA haplotypes containing 1166C (rs5186:A>C), and relevance to metabolic syndrome traits. Human mutation. 2007. Abdollahi Mohammad R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Selective AT1 receptor antagonism enhances sympathetically mediated vasoconstriction in man. Clinical pharmacology and therapeutics. 2007. Lyons D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics. 2005. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. Journal of hypertension. 2005. Spiering Wilko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. The American journal of gastroenterology. 2005. Sookoian Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The thiazide-sensitive Na(+)-Cl(-) cotransporter gene, C1784T, and adrenergic receptor-beta3 gene, T727C, may be gene polymorphisms susceptible to the antihypertensive effect of thiazide diuretics. Hypertension research : official journal of the Japanese Society of Hypertension. 2004. Matayoshi Tetsutaro, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin II type I receptor gene and myocardial infarction: tagging SNPs and haplotype based association study. The Beijing atherosclerosis study. Pharmacogenetics. 2004. Su Shaoyong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The regulation of aldosterone synthase expression. Molecular and cellular endocrinology. 2004. Bassett Mary H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. The pharmacogenomics journal. 2004. Frazier L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. Journal of human hypertension. 2002. Mukae S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis. 2002. Toyofyuku Mamoru, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics. 2002. Baudin Bruno. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. Journal of hypertension. 2001. Kurland L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature medicine. 2001. AbdAlla S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Increased risk for ischaemic events is related to combined RAS polymorphism. Heart (British Cardiac Society). 2001. van Geel P P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney international. 1999. Miller J A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of the angiotensin II type 1 receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypertensive individuals. Hypertension. 1996. Benetos A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. Journal of hypertension. 1995. Hingorani A D, et al. PubMed

LinkOuts

UniProtKB:
AGTR1_HUMAN (P30556)
Q53YY0_HUMAN (Q53YY0)
Ensembl:
ENSG00000144891
GenAtlas:
AGTR1
GeneCard:
AGTR1
MutDB:
AGTR1
ALFRED:
LO000207J
HuGE:
AGTR1
Comparative Toxicogenomics Database:
185
ModBase:
P30556
HumanCyc Gene:
HS07216
IUPHAR Receptor:
AT1 (34)
HGNC:
336

Common Searches